DA-1726
Asset
Oxyntomodulin analogue that activates GLP-1 and glucagon receptors to promote weight loss.
- Stage
- Phase 1
- Modality
- Peptide
- Target
- GLP1R
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Obesity
Phase 1, doi.org, 5 Jun 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Evidence for its targets3
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.